ArticleAmerican journal of translational research2025
Amiodarone combined with metoprolol improves cardiac function in patients with coronary heart disease complicated by arrhythmia.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Amiodarone-metoprolol co-administration enhances heart rate variability and suppresses inflammatory cytokines in tachyarrhythmia patients.American journal of translational research · 2026Article
- Efficacy and safety of levosimendan in acute heart failure patients with different body mass index: a multicenter, retrospective, observational real-world study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of amiodarone combined with metoprolol for improving cardiac function in patients with coronary heart disease (CHD) complicated by arrhythmia.
methodsA retrospective analysis was conducted on 102 patients with CHD and arrhythmia treated at Zhuzhou Central Hospital from January 2018 to March 2021. Patients were divided into two groups: an amiodarone group (n = 48) and a combination group (amiodarone plus metoprolol, n = 54). Primary endpoints included therapeutic efficacy, time to clinical stability and cardioversion, QT dispersion (QTd), heart rate, hemodynamic indices (plasma fibrinogen, hematocrit, plasma viscosity), cardiac function indices (LVEDD, LVEF, LVESD), heart rate variability (HRV) indices (premature contractions, SDNN, SDNNI), myocardial biomarkers, and adverse events. Cardiovascular event rates were also compared using a 3-year follow-up.
resultsThe combination group showed a significantly higher efficacy rate (P<0.05), with faster clinical stabilization and cardioversion (P<0.05). Both groups improved post-treatment, but the combination group showed greater improvements in QTd, heart rate, hemodynamics, cardiac function, HRV indices, and myocardial markers (all P<0.05). Adverse events were significantly lower in the combination group (P<0.001), as was the incidence of cardiovascular events during follow-up (P<0.05).
conclusionAmiodarone combined with metoprolol is a safe and effective strategy for managing CHD complicated by arrhythmia, providing superior improvements in cardiac function and HRV, with a lower rate of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.